Zhaojun Sun

发表

RASSF1A and SIRT6 in non-small cell lung cancer: Relationship with clinical outcome

Tao Chen, Qiang Wang, Fengling Liu, 2017, Oncology letters.

T Cells Induced by Melanoma Vaccines + CD 8 Specific − PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2014 .

Microenvironment and Immunology PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen – Speci fi c CD 8 þ T Cells Induced by Melanoma Vaccines

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2014 .

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

Hong Wang, Joe-Marc Chauvin, Ornella Pagliano, 2013, Cancer research.

Patterns and Trends in Receipt of Opioids Among Patients Receiving Treatment for Cancer in a Large Health System.

H. Bulls, M. Rosenzweig, Y. Schenker, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

The Vacuolar Pathway of Long Peptide Cross-Presentation Can Be TAP Dependent

C. Heirman, K. Thielemans, P. van der Bruggen, 2019, The Journal of Immunology.

Treatment disparities in muscle-invasive bladder cancer: Evidence from a large statewide cancer registry

B. Jacobs, B. Davies, L. Sabik, 2022, Urologic Oncology: Seminars and Original Investigations.

Undertreatment of Prostate Cancer in Rural Residents.

B. Jacobs, B. Davies, L. Sabik, 2019, The Journal of urology.

Human Tumor Antigen-Specific Helper and Regulatory T Cells Share Common Epitope Specificity but Exhibit Distinct T Cell Repertoire

J. Kirkwood, H. Zarour, P. Kúdela, 2010, The Journal of Immunology.

RepertoireSpecificity but Exhibit Distinct T Cell Regulatory T Cells Share Common Epitope Human Tumor Antigen-Specific Helper and

J. Kirkwood, H. Zarour, P. Kúdela, 2010 .

PatientsT Cell Expansion in Melanoma PD-1 Is a Regulator of NY-ESO-1-Specific

J. Kirkwood, C. Sander, S. Land, 2013 .

PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients1

J. Kirkwood, H. Zarour, S. Ferrone, 2009, The Journal of Immunology.

A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors

T. Boon, V. Stroobant, D. Colau, 2006, Cancer Immunology, Immunotherapy.

A polyclonal anti‐vaccine CD4 T cell response detected with HLA‐DP4 multimers in a melanoma patient vaccinated with MAGE‐3.DP4‐peptide‐pulsed dendritic cells

N. Glaichenhaus, G. Schuler, T. Boon, 2005, European journal of immunology.

Changes in Disparities in Stage of Breast Cancer Diagnosis in Pennsylvania After the Affordable Care Act.

L. Sabik, M. Zamanian, Zhaojun Sun, 2020, Journal of women's health.

Monitoring of Anti-Vaccine CD4 T Cell Frequencies in Melanoma Patients Vaccinated with a MAGE-3 Protein1

A. Eggermont, T. Boon, K. Thielemans, 2005, The Journal of Immunology.

Vaccinated with a MAGE-3 Protein Frequencies in Melanoma Patients Monitoring of Anti-Vaccine CD4 T Cell

A. Eggermont, P. Bruggen, K. Thielemans, 2013 .

Epitope Hierarchy of Spontaneous CD4+ T Cell Responses to LAGE-1

J. Kirkwood, H. Zarour, B. Maillère, 2011, The Journal of Immunology.

Epitope Hierarchy of Spontaneous CD4+ T Cell Responses to LAGE-1

J. Kirkwood, H. Zarour, B. Maillère, 2011, The Journal of Immunology.

Identification of Hub Genes as Potential Prognostic Biomarkers in Cervical Cancer Using Comprehensive Bioinformatics Analysis and Validation Studies

H. Xue, Zhaojun Sun, D. Du, 2021, Cancer management and research.

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

J. Kirkwood, H. Zarour, V. Kuchroo, 2010, The Journal of experimental medicine.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2015, The Journal of clinical investigation.

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

Ornella Pagliano, J. Kirkwood, H. Zarour, 2012, Cancer research.

Tumor-Reactive CD4+ T Cell Responses to the Melanoma-Associated Chondroitin Sulphate Proteoglycan in Melanoma Patients and Healthy Individuals in the Absence of Autoimmunity1

G. Schuler, C. Heirman, K. Thielemans, 2007, The Journal of Immunology.

Autoimmunity and Healthy Individuals in the Absence of Sulphate Proteoglycan in Melanoma Patients the Melanoma-Associated Chondroitin T Cell Responses to + Tumor-Reactive CD 4

P. Bruggen, G. Schuler, C. Heirman, 2007 .

Microenvironment and Immunology CD 8 þ T Cells Speci fi c for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1

Ornella Pagliano, J. Kirkwood, H. Zarour, 2012 .

The expression of IL-36 and the activation of pp 38 MAPK and NF-κB p 65 pathway in psoriasis vulgaris

Zhaojun Sun, Yongfeng Yao, Sining Fang, 2017 .

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.

Joe-Marc Chauvin, Ornella Pagliano, J. Kirkwood, 2015, Cancer research.

IL 10 and PD-1 Cooperate to Limit the Activity of Tumor-Speci fi c CD 8 þ T Cells

Joe-Marc Chauvin, Ornella Pagliano, J. Kirkwood, 2015 .

Melanoma and immunotherapy bridge 2015

Andrew J. Park, Ludmila V. Danilova, David C. Smith, 2016, Journal of Translational Medicine.

A Potential Tumor Suppressor Gene Named miR-508-5p Inhibited the Proliferation and Invasion of Human Melanoma Cells by Targeting KIT

Yan Wang, Zhaojun Sun, L. Dang, 2020, Technology in cancer research & treatment.

CD226 opposes TIGIT to disrupt Tregs in melanoma.

D. Davar, Joe-Marc Chauvin, Carmine Menna, 2018, JCI insight.

Multiple Craniofacial Nodules and Plaques Distributed Bilaterally Along Blaschko Lines.

Zhaojun Sun, Fang Yang, L. Bao, 2022, JAMA dermatology.

Insurance type and area deprivation are associated with worse overall mortality for patients with muscle-invasive bladder cancer.

B. Jacobs, B. Davies, L. Sabik, 2023, Urology.

Phase IB study of pembrolizumab (Pembro) and pegylated-interferon alfa-2b (Peg-IFN) in advanced melanoma (MEL).

D. Davar, Joe-Marc Chauvin, Ornella Pagliano, 2016 .

Disparities in Geographic Access to Medical Oncologists.

B. Jacobs, L. Sabik, Zhaojun Sun, 2022, Health services research.

Effects of CAR-T Cell Therapy on Immune Cells and Related Toxic Side Effect Analysis in Patients with Refractory Acute Lymphoblastic Leukemia

Zhaojun Sun, Rui Zhang, Jie Gao, 2023, Mediators of inflammation.

Targeting PD-1 and Tim-3 pathways to reverse tumor antigen-specific CD4+ T cell dysfunction in patients with advanced melanoma (66.1)

J. Kirkwood, H. Zarour, V. Kuchroo, 2011, Journal of Immunology.

Study of anti-PD-1 antibody pembrolizumab and pegylated-interferon alfa-2b (Peg-IFN) for advanced melanoma.

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2015 .